NIH Technology Opportunity Webinar: Automated Acoustophoresis Benchtop Device to Radio-Label & Isolate Cells for Immunotherapy Treatment

Published on :

Register to attend a free NIH webinar. Attendees will learn about the research behind a proposed, automated benchtop device for labeling immunotherapy cells with 89Zr-oxine for Positron Emission Tomography (PET) [….]

NCI Technology Opportunities Webinar: GPC1 as a New Therapeutic Target in Pancreatic Cancer: Development of Antibodies and CAR-T

Published on :

Register to attend a free NIH webinar. Attendees will learn about a new targeted immunotherapy pancreatic cancer treatment centered on the Glypican-1 (GPC1) cell surface heparan sulfate proteoglycan protein which [….]

2023 National Cancer Institute and Frederick National Laboratory Technology Showcase

Published on :

Registration is open for the 2023 Technology Showcase, the annual event highlighting how potential industry partners can work with the NCI and Frederick National Laboratory (FNL). You can choose to attend either in-person at the Frederick National Laboratory or online.

NIH and Disc Medicine Partner to Help Bring Anemic Patients Out From the Shadows

Published on :

Disc Medicine, based in Watertown, MA, is extending a hand to help bring patients with anemia and other hematologic diseases out from the shadows to live more normal lives. And their recent partnership with the National Heart Lung and Blood Institute (NHLBI), a branch of the NIH in Bethesda, Maryland is extending that reach even further.

NIH launches first phase of $9.8 million competition to accelerate development of neuromodulation therapies

Published on :

The National Institutes of Health has launched the first phase of the Neuromod Prize, a $9.8 million competition to accelerate the development of neuromodulation therapies — targeted treatments that adjust nerve activity to improve organ function. The competition seeks scientists, engineers, and clinicians to submit novel concepts and clinical development plans to demonstrate solutions for precisely stimulating the peripheral nervous system to treat disease and improve human health. The first phase of the competition will award up to $800,000. NIH plans to launch a second phase awarding up to $4 million, and a third phase awarding up to $5 million, subject to the availability of funds. Details of the requirements and registration for phases 2 and 3 are expected to be announced at a future time. NIH is launching only phase 1 at this time.

Rockville’s Integrated BioTherapeutics Inc. Awarded $16.3M Contract from the National Institute of Allergy and Infectious Diseases to Develop a Treatment for Marburg Virus Disease

Published on :

Integrated BioTherapeutics Inc. (IBT), a Maryland biotechnology company specializing in emerging infectious diseases, announced today the receipt of a contract valued at up to $16.3 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop IBT-T03H, a monoclonal antibody for treatment of Marburg virus disease (MVD). MVD is caused by either of two marburgviruses, Marburg virus and Ravn virus, and has reemerged several times since it was initially described in 1967. IBT-T03H, discovered in collaboration with the University of Maryland, has been shown in preclinical studies to be protective against both Marburg and Ravn virus.